GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » EBITDA Margin %

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) EBITDA Margin % : -25,040.91% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Great Novel Therapeutics Biotech & Medicals's EBITDA for the six months ended in Dec. 2023 was NT$-22.04 Mil. Great Novel Therapeutics Biotech & Medicals's Revenue for the six months ended in Dec. 2023 was NT$0.09 Mil. Therefore, Great Novel Therapeutics Biotech & Medicals's EBITDA margin for the quarter that ended in Dec. 2023 was -25,040.91%.


Great Novel Therapeutics Biotech & Medicals EBITDA Margin % Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals EBITDA Margin % Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial -32,720.45 - -5,559.05 -9,992.04 -1,132.27

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -5,560.00 -5,131.30 - -690.45 -25,040.91

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's EBITDA Margin %

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Great Novel Therapeutics Biotech & Medicals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's EBITDA Margin % falls into.



Great Novel Therapeutics Biotech & Medicals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Great Novel Therapeutics Biotech & Medicals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-54.915/4.85
=-1,132.27 %

Great Novel Therapeutics Biotech & Medicals's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-22.036/0.088
=-25,040.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Great Novel Therapeutics Biotech & Medicals  (ROCO:7427) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Great Novel Therapeutics Biotech & Medicals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines